The North America Prosthetic Heart Valve Market would witness market growth of 10.1% CAGR during the forecast period (2022-2028).
A prosthetic heart valve, also called an artificial heart valve, is a one-way valve that is placed into a patient's heart to replace a malfunctioning heart valve. Mechanical heart valves, bioprosthetic tissue valves, and designed tissue valves are the three types of artificial heart valves. Prosthetic heart valves are rapidly being used to replace native heart valves that need to be replaced. The purpose of an artificially implanted valve is for it to function like a natural valve in terms of hemodynamics and side effects (low thrombogenicity). Bioprosthetic valves have similar functional features to native valves (e.g., hemodynamics, thrombosis resistance), but their lifetime is limited compared to mechanical valves.
The tricuspid, pulmonary, mitral, and aortic valves are four valves that open and close when blood flows through the heart. The right atrium is where blood enters the heart and travels to the right ventricle via the tricuspid valve. Blood is then directed into the lungs via the pulmonary valve. After being oxygenated, blood travels to the left atrium, where it is pumped to the left ventricle via the mitral valve. The aortic valve transports blood from the left ventricle to the aorta. Birth defects, age-related changes, and impacts from other conditions, such as rheumatic fever and infections that cause endocarditis, are all possible causes of heart valve deterioration.
There is a significant prevalence of valvular heart diseases in the United States. According to the Center for Disease Control and Prevention, valvular heart disease affects about 2.5% of the population in the United States. Valvular heart disease affects about 13% of people born before 1943. The mitral valve (which has only two leaflets and the aortic valve are the most usually impacted by rheumatic heart disease, although any valve can be impacted, and more than one can be involved. Bicuspid aortic valves (those with only two leaflets instead of the usual three) affect approximately 1% to 2% of the population and are more common in men. In the United States, there were 3,046 deaths from rheumatic valvular heart disease in 2017 and 24,811 deaths from non-rheumatic valvular heart disease.
Moreover, Mitral Valve Disease is one of the most prevalent heart valve diseases in the United States, which compels a significant number of people to go under a heart valve transplant surgery. Therefore, due to the surging prevalence of valvular diseases in the region, the demand for prosthetic heart valves is estimated to increase. This factor is bolstering the growth of the regional prosthetic heart valve market.
The US market dominated the North America Prosthetic Heart Valve Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $3,508.5 million by 2028. The Canada market is estimated to grow at a CAGR of 12.6% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 11.6% during (2022 - 2028).
Based on End User, the market is segmented into Hospitals & Cardiac Centers and Ambulatory Surgical Centers & Others. Based on Product, the market is segmented into Transcatheter, Tissue, and Mechanical. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Prosthetic Heart Valve Market is Estimated to reach $13.3 Billion by 2028, at a CAGR of 10.7%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boston Scientific Corporation, Medtronic PLC, Abbott Laboratories, Meril Life Science Private Limited, Colibri Heart Valve LLC, Artivion, Inc., TTK Healthcare Limited, Edwards Lifesciences Corporation, JenaValve Technology, Inc., and Micro Interventional Devices, Inc.
By End User
By Product
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 